Voyager Therapeutics alternatives

Several gene therapy firms have developed proprietary AAV capsids for CNS delivery. REGENXBIO and uniQure emphasize liver and CNS targeting while Sarepta focuses on muscle and cardiac indications; none publicly match Voyager’s reported IV blood-brain barrier performance in preclinical models.

Voyager prioritizes Alzheimer’s and ALS gene therapies using TRACER-derived capsids. Sarepta’s approved products target Duchenne muscular dystrophy with different vectors and delivery routes, making direct overlap limited despite both operating in genetic medicines.

No approved gene therapies exist for Alzheimer’s. Clinical-stage competitors like those using CRISPR or antisense approaches may reach later trials sooner, but Voyager’s VY7523 and VY1706 remain early with unique capsid advantages still under evaluation.

Novartis Gene Therapies (formerly AveXis) has an approved SMA treatment using AAV9. Voyager has no approved products yet, positioning it earlier in the regulatory timeline than companies with commercial CNS assets.

Most CNS gene therapy competitors rely on viral vectors. Voyager’s mention of non-viral approaches places it among a smaller group exploring lipid nanoparticles or other methods, though these remain largely preclinical across the industry.

Voyager concentrates exclusively on neurological diseases with a proprietary capsid platform. Bluebird and CRISPR have broader pipelines including blood disorders and ex vivo editing, offering different risk profiles, manufacturing needs, and market focus than Voyager’s IV-administered CNS strategy.